Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Poxel Announces Participation in Two Upcoming Investor Conferences

Poxel SA
Posted on: 09 Nov 16

POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for type 2 diabetes, today announced that it will be featured as a presenting company at the Roth Capital Partners 29th Annual Conference and at the Oppenheimer 27th Annual Healthcare Conference.

The Roth Capital Partners Conference is being held on March 12-17th at The Ritz Carlton hotel in Dana Point, CA. The Company will present a corporate overview on Tuesday, March 14th at 10:00 am Pacific Time in PINK Salon 5 and will be available to participate in one-on-one meetings with investors.

The 27th Annual Oppenheimer Healthcare Conference will be held on March 21-22th at the Westin Hotel New York Grand Central in New York City. The Company will present a corporate overview on Tuesday, March 21st at 1:00 pm Eastern Time in the Ambassador Room and will be available to participate in one-on-one meetings with investors. The presentation at the Oppenheimer conference will be webcast live. To access the Oppenheimer webcast, please visit the following link https://www.veracast.com/webcasts/opco/healthcare2017/26108161893.cfm. The webcast replay will remain available for 90 days following the live presentation.

About Poxel SA

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of type 2 diabetes. We have successfully completed our Phase 2 trials for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S. and EU and have fully enrolled a Phase 2b clinical study in Japan. Our second program, PXL770, a direct AMPK activator, is in Phase 1 development. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)

View source version on businesswire.com: http://www.businesswire.com/news/home/20170308006301/en/

Business Wire
www.businesswire.com

Last updated on: 09/03/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.